Anti-Tumor Efficacy of a Mesothelin-Based Nanovaccine in a KPC Orthotopic Mouse Model of Pancreatic Cancer.

Vaccines (Basel) · 2025 · PMC11946167 · PMID 40266223

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

While treatment with NPs containing only adjuvants or only the MSLN peptide also showed a trend towards lower primary tumor size, aggressiveness, and metastasis scores in comparison to controls, these alterations were not significant. 3.6.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.